Last reviewed · How we verify

CLOMIPHENE

FDA-approved approved Small molecule Quality 40/100

Clomiphene is a marketed drug primarily indicated for ovulatory dysfunction, holding a significant position in the fertility treatment market. Its key strength lies in its well-established mechanism and long-term use, supported by a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent expiration approaches, which could erode market share and revenue.

At a glance

Generic nameCLOMIPHENE
ModalitySmall molecule
PhaseFDA-approved
First approval1967

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: